Nuclear matrix protein fluid assay
US5840503A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 18, 1995 |
| Grant date | Nov 24, 1998 |
| Priority date | — |
| Expiry date | May 18, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/961
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Disclosed is a method for evaluating the efficacy of a therapy associated with cell death in a patient undergoing such a therapy. The method involves providing at least two body fluid samples drawn from the patient, wherein a second sample is drawn from the patient after a first sample, and measuring the quantity per unit volume of a body-fluid soluble interior nuclear matrix protein in each of the samples. By comparing the quantity per unit volume of the body fluid-soluble interior nuclear matrix protein in the first sample with the quantity per unit volume of the body fluid-soluble interior nuclear matrix protein in the second sample, it is possible to determine whether there has been an increase or decrease of cell death in the patient during therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.